Moderna Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2010)
Status: Acquired by Indevus Pharmaceuticals (2006) → now Bristol-Myers Squibb (2001)

Organization Overview

First Clinical Trial
2015
NCT03076385
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Moderna Therapeutics | ModernaTX, Inc. | Valera Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acidosis (Phase 2)

Amino Acid Metabolism, Inborn Errors (Phase 2)

Chikungunya Fever (Phase 1)

Cytomegalovirus Infections (Phase 2)

Infections (Phase 2)

Influenza, Human (Phase 1)

Lymphoma (Phase 1)

Melanoma (Phase 2)

Metabolism, Inborn Errors (Phase 2)

Neoplasms (Phase 1)

Paramyxoviridae Infections (Phase 1)

Propionic Acidemia (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Virus Diseases (Phase 1)

Zika Virus Infection (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 80
  • # of Trial APIs: 50